BioWa Licenses POTELLIGENT® Technology to GSK for Use in Antibody Development and Commercialization
News Dec 09, 2008
BioWa, Inc., announced has that it licensed to GlaxoSmithKline its POTELLIGENT® Technology for use in developing and commercializing select GSK antibodies with enhancement of antibody-dependent cellular cytotoxicity (ADCC).
"GSK is recognized as a key player in the field of antibody drug discovery," said Dr. Masamichi Koike, BioWa President and CEO. "We believe this represents an important opportunity to promote the development of more effective targeted treatments for debilitating diseases where enhanced ADCC might offer a significant therapeutic benefit."
Under the terms of the agreement, BioWa will provide GSK with non- exclusive commercial rights to use the technology for multiple antibodies. In return, BioWa will receive technology access fees, and may receive milestone payments and royalties from resulting products which are developed by GSK. Additional terms were not disclosed.